Vivimed announces the Export of 1st shipment to Canada - Famotidine tablets 40mg and 20mg equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Vivimed Labs jumped 4.77% to Rs 29.65 after the company announced the first export shipment of famotidine tablets to Canada.Vivimed Labs announced the export of first shipment of famotidine tablets (40mg and 20mg) to Canada. The drug is manufactured at the company s Hyderabad facility.
Famotidine is an histamine H₂ receptor antagonist medication that decreases stomach acid production. The drug is used for the relief of heartburn, indigestion, upset stomach, sour stomach due to excess stomach acid, hyperacidity and/or acid indigestion. It is also used for the prevention of the symptoms of excess stomach acid brought on by consuming food and/or beverages which may cause symptoms.
NEW DELHI:
Vivimed Labs, a Hyderabad-based drug maker with a market cap of Rs 260 crore, has had an interesting week.
On May 10, it received government approval to manufacture Favipiravir, which lifted its share price up 27 per cent within just 4 sessions. However, it didn’t take much to turn the tides against it.
As Covid-19 cases decline gradually, investors are now running away from the counter. On Monday, the scrip hit the 5 per cent lower circuit at Rs 31.20. Investors believe that with the decline in cases, the demand for Favipiravir will also come down.
Favipiravir is used for the treatment of mild to moderate cases of Covid-19. It is one of the leading oral anti-viral treatment approved in various countries for the potential treatment of Covid-19 patients.
Vivimed Labs Gains On Receiving Government s Approval To Make Favipiravir Favipiravir is indicated to treat mild to moderate cases of Covid-19 infection and is in short supply owing to rising Covid-19 infections in the country.
Updated: May 10, 2021 12:19 pm IST
Shares of the Hyderabad-based drug maker - Vivimed Labs - were locked in a five per cent upper circuit at Rs 28.45 after it received government of India s approval to manufacture and market Favipiravir Tablet 200 mg and 400 mg for Indian market. Vivimed Labs Limited, a niche specialty chemicals and pharmaceuticals company, announced today, the receipt of Government of India (Director General of Health Services) approval to manufacture and market Favipiravir Tablet 200 mg and 400 mg under Vivimed s own brand name Favulous across India, the company said in a press release.
Vivimed announces the receipt of Government of India approval to Manufacture and market Favipiravir Tablet 200 mg & 400 mg for Indian Market equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.